1. Academic Validation
  2. Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice

Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice

  • Nat Commun. 2023 Feb 13;14(1):802. doi: 10.1038/s41467-023-36519-8.
Hanseul Park # 1 Byounggook Cho # 1 Hongwon Kim # 1 Takashi Saito 2 3 Takaomi C Saido 2 Kyoung-Jae Won 4 Jongpil Kim 5
Affiliations

Affiliations

  • 1 Department of Chemistry, Dongguk University, Seoul, 100-715, Republic of Korea.
  • 2 Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako-shi, Saitama, Saitama, Japan.
  • 3 Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
  • 4 Department of Computational Biomedicine, Cedars-Sinai Medical Center 700 N, San Vicente Blvd., West Hollywood, CA, USA. [email protected].
  • 5 Department of Chemistry, Dongguk University, Seoul, 100-715, Republic of Korea. [email protected].
  • # Contributed equally.
Abstract

Alzheimer's disease (AD) is associated with progressive neuronal degeneration as amyloid-beta (Aβ) and tau proteins accumulate in the brain. Glial cells were recently reported to play an important role in the development of AD. However, little is known about the role of oligodendrocytes in AD pathogenesis. Here, we describe a disease-associated subpopulation of oligodendrocytes that is present during progression of AD-like pathology in the male AppNL-G-F and male 5xFAD AD mouse brains and in postmortem AD human brains using single-cell RNA sequencing analysis. Aberrant ERK1/2 signaling was found to be associated with the activation of disease-associated oligodendrocytes (DAOs) in male AppNL-G-F mouse brains. Notably, inhibition of ERK1/2 signaling in DAOs rescued impaired axonal myelination and ameliorated Aβ-associated pathologies and cognitive decline in the male AppNL-G-F AD mouse model.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50846
    99.27%, ERK1/2 Inhibitor
    ERK